| P50 | author | Jarmo T Laitinen | Q48131809 |
| P2093 | author name string | Susanna M Saario | |
| P2860 | cites work | Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | Q24309438 |
| | N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo | Q24532188 |
| | Brain monoglyceride lipase participating in endocannabinoid inactivation | Q24533828 |
| | Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase | Q24555807 |
| | 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor | Q24620096 |
| | Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro | Q24673383 |
| | Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes | Q24673517 |
| | Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling | Q27640068 |
| | Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism | Q28138523 |
| | An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors | Q28185158 |
| | Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene | Q28208449 |
| | Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor | Q28218654 |
| | Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 |
| | A second endogenous cannabinoid that modulates long-term potentiation | Q28248073 |
| | Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase | Q46718450 |
| | Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 |
| | Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid typ | Q46801175 |
| | Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia | Q46826807 |
| | Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia | Q46868894 |
| | Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. | Q48254078 |
| | Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase | Q48634796 |
| | Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish | Q55871276 |
| | cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases | Q28252158 |
| | A FAAH-regulated class of N-acyl taurines that activates TRP ion channels | Q28253967 |
| | URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain | Q28259933 |
| | Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus | Q28268567 |
| | Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus | Q28286042 |
| | 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain | Q28290395 |
| | Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 |
| | Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds | Q28294909 |
| | Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides | Q28295481 |
| | Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 |
| | Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells | Q28378272 |
| | Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 |
| | Modulation of anxiety through blockade of anandamide hydrolysis | Q29615902 |
| | Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis | Q34234907 |
| | Functional disassociation of the central and peripheral fatty acid amide signaling systems | Q34332678 |
| | Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor | Q34358410 |
| | Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase | Q34385277 |
| | An endocannabinoid mechanism for stress-induced analgesia. | Q34428429 |
| | A second fatty acid amide hydrolase with variable distribution among placental mammals | Q34570802 |
| | Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol | Q35048362 |
| | Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor | Q35048967 |
| | Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models | Q35545219 |
| | Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). | Q36533477 |
| | Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension | Q37373710 |
| | Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms | Q38757749 |
| | Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells | Q40158906 |
| | Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors | Q40174517 |
| | Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. | Q40525710 |
| | Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages | Q40935411 |
| | The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors | Q41584525 |
| | Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors | Q41832173 |
| | The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide | Q42108464 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo | Q44028862 |
| | Possible endocannabinoid control of colorectal cancer growth | Q44569526 |
| | Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity | Q44903331 |
| | Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors | Q44926114 |
| | Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality | Q44926848 |
| | Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. | Q44963304 |
| | Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. | Q45173372 |
| | Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels | Q46553209 |
| | Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla | Q46675581 |
| | Fatty acid amide hydrolase controls mouse intestinal motility in vivo | Q46687826 |
| P433 | issue | 5 | |
| P921 | main subject | endocannabinoids | Q10483908 |
| P304 | page(s) | 287-293 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors | |
| P478 | volume | 101 | |